Active ingredientMiriplatinCat. No. P-M139-001CAS 141977-79-9Family · Pharmaceutical analytical standards
Miriplatin
A third-generation platinum-based anticancer drug, introduced in Japan in 2010 for hepatocellular carcinoma: it is given directly into the hepatic artery during chemoembolisation. This family brings together the active ingredient, pharmacopoeial impurities and other impurities.
Did you know?Its two long chains of myristic acid, a fatty acid, make it so lipophilic that it can be suspended in an iodised oily contrast medium, visible on X-rays.
Go to the active ingredient →Active ingredientMiriplatinCat. No. P-M139-001CAS 141977-79-9
ImpurityMiriplatin Impurity 1Cat. No. P-M139-005CAS 104276-92-8
Pharmacopoeial impurityOxaliplatin USP Related Compound BCat. No. P-M139-008CAS 66900-68-3
ImpurityMiriplatin Impurity 2Cat. No. P-M139-009
Pharmacopoeial impurityOxaliplatin EP Impurity B DinitrateCat. No. P-M139-011CAS 94042-08-7
ImpurityMiriplatin Impurity 4Cat. No. P-M139-016CAS 61848-62-2No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.